Facebook picto   picto linkdink   picto tiwter

Management and Board of Directors



Marc Oczachowski / Chief Executive Officer

Marc Oczachowski joined the company in May 1997 as Area Sales Manager, based in Lyon, France. From March 2001 to January 2004, he held management positions as General Manager of EDAP Technomed Malaysia. He was appointed Chief Operating Officer of EDAP TMS in November 2004 and became Chief Executive Officer of the Company in March 31, 2007. On July 1, 2012, he relocated in Austin, Texas (USA), for a five years period, to manage US operations. Previously he worked for Sodem Systems - power tools for orthopedic - as Area Sales Manager. He is a graduate of Institut Commercial de Lyon, France.

François Dietsch / Chief Financial Officer

François Dietsch joined EDAP in 2005 as Internal Audit and Consolidation Manager, leading the implementation of internal controls for Sarbanes-Oxley Compliance, consolidation of financial statements from the Company's subsidiaries and preparation of financial statements in accordance with U.S. GAAP, including EDAP's annual report on Form 20-F. In 2012, he was promoted to Group Financial Control Manager and Finance Manager of EDAP's French subsidiary where, in addition to his previous responsibilities, he managed accounting firm relationships at the subsidiary level and was the primary liaison between the Company and its external auditors. He also managed the Finance department at EDAP France. In July 2015, he was promoted Chief Financial Officer of the Company. Prior to joining EDAP he held finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds Master's Degrees in Management and Corporate Finance from University of Paris Dauphine.

Board of Directors

Philippe Chauveau / Independent Director
Chairman of the Board of Directors - Director Since: 1997 

In 1997, Philippe Chauveau was named chairman of EDAP TMS S.A. Supervisory Board, involving a two-tier board structure overseeing an Executive Board. In 2002, both these boards were replaced by a single Board of Directors, which Philippe Chauveau headed as Chairman and CEO. While remaining Chairman of the Board, he was succeeded by Hugues de Bantel, as CEO, in 2004. Philippe Chauveau, since 2000, is also Chairman of the Board of SCYNEXIS Inc., funded by private equity, which is an innovative drug discovery company, based in the USA, partnering with major pharmaceutical companies worldwide. He is also personal executive coach to senior research leaders at HOFFMANN LaROCHE in Switzerland. He was R&D Vice-President at AT&T BELL LABS; he had been Chairman of APPLE COMPUTER Europe, preceded by increasing marketing roles in ITT and in PROCTER & GAMBLE. Philippe Chauveau has a French, Anglo-Irish and American education and culture. He has an Honours Degree from Trinity College Dublin with a BA., and a Bsc.

Pierre Beysson / Independent Director
Director, Audit Committee Chair - Director Since: 2002
EDAP TMS S.A. Committee Membership: Audit Committee

Pierre Beysson was elected as a member of the Board of Directors in September 2008. Pierre Beysson was then the Chief Financial Officer of Compagnie des Wagons-Lits ("CWC"), the on-board train service division of Accor, a French multinational Hotel and Business Services Group. In this capacity he sat in a number of boards of companies related to the Accor Group. He is now an M&A consultant. Prior to his assignment at CWL, Pierre Beysson has held a number of senior financial positions with Nixdorf Computers, Trane (Air Conditioning), AM International (Office Equipment) and FMC (Petroleum Equipment). His background also includes Industrial Project & Distribution Network Management with Computervision (Computed Aided Design) and Customer Service & Distribution Network Management with Siemens-Nixdorf International. Pierre Beysson was trained as a CPA, has auditing experience and holds an MBA from Havard Business School.

Rob Michiels / Independent Director
Director Since: 2009
EDAP TMS S.A. Committee Membership: Audit Committee

Rob Michiels was elected as a member of the Company's Board of Directors in July 2009. He is a 30plus-year veteran of the US medical device industry, both in corporate positions and as a startup entrepreneur. He most recently served as Chief Executive Officer (CEO) of CardiAQ™ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation and which was acquired by Edwards Lifesciences during the second half of 2015. He previously served as Chief Operating Officer (COO) of CoreValve (acquired by Medtronic); and as President and COO of InterVentional Technologies (acquired by Boston Scientific). He helped drive both companies from cardiovascular start-ups to established market leaders, using new and innovative technologies which have strong synergies to the HIFU story. Rob Michiels is director of Aegis Surgical Ltd, Atrius Ltd, FEops NV and Embolization Prevention Technologies, all privately held companies developing cutting edges cardiovascular less invasive technologies. Rob Michiels is a founding partner of CONSILIUM, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch languages, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Master in business administration (MBA) from Indiana University.

Dr. Argil Wheelock / Independent Director
Director Since: 2009
EDAP TMS S.A. Committee Membership: Audit Committee 

Dr. Argil Wheelock was elected as a member of the Company's Board of Directors in June 2009. Dr. Wheelock, a U.S. board certified urologist, is currently Chief of Urology at Erlanger Medical Center, a tertiary care and teaching hospital in Chattanooga, Tennessee. He is Chief Medical Advisor to HealthTronics Inc., a subsidiary of Endopharmaceuticals, a NASDAQ company. Healtronics is a leading U.S. provider of urological services and products. From 1996 to 2005, Dr. Wheelock served as Chairman and CEO of HealthTronics, a publicly traded NASDAQ company where he was a founder. He has built a successful track record introducing new medical devices to the U.S. and navigating the FDA approval process. He is widely known among the U.S. urological community for bringing clinical benefits to patients and economic value to urology practices. Dr. Wheelock graduated from the University of Tennessee College of Medicine and completed urological training at Mount Sinai Hospital in New York City.